Regeneron Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (66)

Latest Posts

About This Stock More About This Stock
Regeneron (REGN) Beats On Q1 Earnings
Article By: Zacks Investment Research
Thursday, May 3, 2018 10:07 AM EDT
Regeneron’s first-quarter 2018 earnings topped expectations. Our consensus called for EPS of $4.51 and the company reported EPS of $4.67.
In this article: REGN
Read
Regeneron Pharmaceuticals: Sequencing Its Way To +30% Upside
Article By: Matthew Hogan
Thursday, May 3, 2018 6:05 AM EDT
Regeneron's stock price fall over the last 10 months is not supported by the numbers. With a broadening portfolio of drugs on the market, the company is set to prove to investors that it is not a one-trick pony.
In this article: REGN Also: AET, CCE, CI, CVS, AVGO, CELG, ESRX, VRTX, YY, CC
Read
Morning Call For Monday, April 9
Article By: Jim Van Meerten
Monday, April 9, 2018 10:54 AM EDT
Chicago Fed President Evans said the Fed should continue gradually raising interest rates if data on consumer prices indicate inflation will soon reach its 2% target. Stocks are up as global markets rally on reduced US-China trade concerns.
In this article: DFS, GM, SYNA, KOOL, OLED, QCOM, SWKS, QRVO, BA, BEN, REGN, IAC, A, AMTD
Read
Bull Of The Day: Regeneron
Article By: Kevin Cook
Wednesday, March 14, 2018 10:53 AM EDT
Regeneron Pharmaceuticals shares have been on an odyssey in the past year, soaring from $360 last April up to $540 by June and then entering their own private bear market since last autumn to dip below $320 this year.
In this article: REGN Also: SNY, AMGN, BIIB, GILD
Read
3 Biotech Stocks With Rising Earnings Estimates Post Q4
Article By: Zacks Investment Research
Tuesday, March 13, 2018 4:17 PM EDT
The Q4 earnings season for the pharma/biotech sector was scattered with a few small biotech companies yet to report. The releases so far provide us with a clear picture of the sector’s performance.
In this article: LGND, REGN, HZNP Also: SNY, AMGN, BIIB, CELG, GILD, VRTX
Read

PARTNER HEADLINES

Latest Tweets for $REGN

No tweets yet!

$REGN

Regeneron Pharmaceuticals’ Dupixent Has Multi-Billion-Dollar Potential: Polen Capital
David J. Tanner 1/31/2018 3:55:05 AM

Note it has only been approved in Japan. And only for those whom existing treatments are ineffective. So that's a MUCH smaller market. How small I don't know. But not enough to make me bite. $REGN

1 to 1 of 1 comments